ArticleMaterials today. Bio2025
Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blocking the CD47-SIRPα signaling pathway to promote macrophage phagocytosis represents a promising strategy for cancer therapy. RNA interference offers a safe and efficient means to disrupt this pathway, highlighting the importance of developing effective siRNA delivery systems to improve antitumor efficacy. In this study, we developed a biomimetic and fusogenic liposome capable of deep tumor penetration and selective tumor cell targeting for the coordinated cytosolic delivery of CD47 and PLK1-targeting siRNAs. CD47 siRNA downregulated CD47 protein expression, suppressing the "don't eat me" signal, while PLK1 siRNA induced tumor cell apoptosis and enhanced the "eat-me" signal by facilitating the translocation of calreticulin to the cell surface. This biomimetic platform enabled efficient tumor cell specific cytosolic delivery and deep tissue penetration of siRNAs. The combined silencing strategy significantly enhanced macrophage-mediated phagocytosis of tumor cells and improved antitumor outcomes in a 4T1 tumor-bearing mouse model. Overall, this study presents a biomimetic fusogenic liposomal system that amplifies macrophage phagocytosis and suppresses tumor growth, providing a promising therapeutic avenue for triple-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.